SELLAS Life Sciences Grou... (SLS)
0.97
0.04 (4.47%)
At close: Jan 15, 2025, 2:26 PM
undefined% (undefined)
| Bid | 0.96 |
| Market Cap | 68.33M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -1.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.97 |
| Volume | 663,553 |
| Avg. Volume (20D) | 1,186,091 |
| Open | 1.00 |
| Previous Close | 0.93 |
| Day's Range | 0.95 - 1.01 |
| 52-Week Range | 0.50 - 1.72 |
| Beta | undefined |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cance...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2008
Employees 16
Stock Exchange NASDAQ
Ticker Symbol SLS
Analyst Forecast
According to 1 analyst ratings, the average rating for SLS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 208.99% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago ·
Source
+4.59%
SELLAS Life Sciences Group shares are trading high...
Unlock content with
Pro Subscription
6 months ago ·
Source
-0.82%
SELLAS Life Sciences shares are trading higher after the company was granted FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor for the treatment of pediatric acute lymphoblastic leukemia, making it eligible for a priority review voucher worth over $100 million upon approval.
